Scancell Holdings Plc (SCLP) Rating Reiterated by Panmure Gordon
Scancell Holdings Plc (LON:SCLP)‘s stock had its “buy” rating restated by investment analysts at Panmure Gordon in a note issued to investors on Friday. They currently have a GBX 68 ($0.91) price objective on the stock. Panmure Gordon’s price objective indicates a potential upside of 300.00% from the stock’s current price.
Shares of Scancell Holdings Plc (LON:SCLP) opened at 16.30 on Friday. Scancell Holdings Plc has a 12 month low of GBX 12.00 and a 12 month high of GBX 29.06. The firm’s market capitalization is GBX 36.67 million. The firm’s 50-day moving average price is GBX 18.35 and its 200 day moving average price is GBX 17.56.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/16/scancell-holdings-plc-sclp-rating-reiterated-by-panmure-gordon.html
Scancell Holdings Plc Company Profile
Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects.
Receive News & Ratings for Scancell Holdings Plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Scancell Holdings Plc and related companies with MarketBeat.com’s FREE daily email newsletter.